论文部分内容阅读
目的通过检测血浆同型半胱氨酸等项目观察两种胰岛素类似物治疗2型糖尿病的临床疗效。方法将81例2型糖尿病患者随机分为2组:A组单纯应用胰岛素类似物诺和锐30治疗,B组单纯应用胰岛素类似物优泌乐25治疗。3个月后观察2组患者血浆总同型半胱氨酸(tHcy)、空腹血糖(FBG)、餐后2h血糖(P2hBG)和糖化血红蛋白A1c(HbA1c)及体质指数(BMI)情况。结果(1)治疗后2组tHcy、FBG、P2hBG、HbA1c均低于治疗前(P均<0.05)。(2)两种胰岛素类似物治疗后各指标的比较差异无统计学意义(P均>0.05)。结论胰岛素类似物治疗2型糖尿病血糖控制明显,且血浆tHcy水平也明显下降。
Objective To observe the clinical efficacy of two kinds of insulin analogues in the treatment of type 2 diabetes by detecting plasma homocysteine and other items. Methods Eighty-one patients with type 2 diabetes were randomly divided into 2 groups: group A was treated with Novo-Rui-30, a simple insulin analogue, and group B with insulin analogue Muestro-25 alone. After 3 months, the plasma total homocysteine (tHcy), fasting blood glucose (FBG), postprandial 2h glucose (HbA1c) and body mass index (BMI) were observed. Results (1) The levels of tHcy, FBG, P2hBG and HbA1c in the two groups after treatment were lower than those before treatment (all P <0.05). (2) There was no significant difference between the two insulin analogs after treatment (P> 0.05). Conclusion Insulin analogue is effective in treating type 2 diabetes with glycemic control and plasma tHcy levels are also significantly decreased.